TrialThe Journal of antimicrobial chemotherapy2024

A detailed characterization of drug resistance during darunavir/ritonavir monotherapy highlights a high barrier to the emergence of resistance mutations in protease but identifies alternative pathways of resistance.

Adam Abdullahi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.